Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease

Chronic kidney disease affects ~10% of people worldwide and there are no disease modifying therapeutics that address the underlying cause of any form of kidney disease. Genome wide association studies have identified the G1 and G2 variants in the apolipoprotein L1 ( APOL1 ) gene as major contributor...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 16; no. 1; pp. 167 - 13
Main Authors Zimmerman, Brandon, Dakin, Leslie A., Fortier, Anne, Nanou, Evanthia, Blasio, Angelo, Mann, James, Miller, Howard, Fletcher, Marissa, Wang, Tiansheng, Nanthakumar, Suganthini, McCarthy, Gizelle, Matar, Caline, Matsye, Prachi, Wang, Guanyu, Snyder, Phillip, Daniel, Kevin, Swamy, Harsha, Sullivan, Kelly, Bright, Franklin, Powers, Audrey, Gagnon, Kevin J., Lu, Fan, Paula, Steven, Khare-Pandit, Suvarna, Henry, Larry, Hamel, Martine, Denis, Francois, Nicolas, Olivier, Hariparsad, Niresh, Kumar, Shyamesh, Proctor, Jennifer, Senter, Timothy, Furey, Brinley, Bunnage, Mark E.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 02.01.2025
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…